The numbers refer to the bibliography below
The Biotherapy Infusion D'Abramo (from now on " BIDA " ) , discovered and registered by Dr. Emanuele Ugo D'Abramo , should not be considered a " therapeutic treatment " in the strict sense . Or at least not in the sense in which the medicine called " conventional" asks us to address the issue of care.
Another prerequisite to a reasoned reading of the pharmacological and clinical considerations that make up this report is that the adjuvant treatment described here is built upon the foundations on strong roots of the cd . Holistic Medicine (1,2). This is too often considered a " branch" Medical - almost a specialization - rather than, as more correctly it seems appropriate not to treat a simple semantics, a mental model of the Doctor does not just consider the patient as a sum of organs and functions, but a unique indivisible , composed of spirit , mind and body : elements that interact in well-being , as well as in disease states : determining the onset and influencing the trend.
The scientific basis of reference and support for this mental model are represented by a multitude of scientific research in the medical, pharmacological, biochemical , wonderfully illustrated and systematized in a single set , defined Psyco Neuro Endocrine Immunology ( 3). This report also refers to this knowledge , all widely available in the landscape of biomedical most accepted by the scientific community independently.
In light of these premises, we describe the BIDA as a complementary treatment, integrative, and alternative therapies suggested by the guidelines, protocols or colleagues, each according to his experience, his knowledge and his conscience . Not part of the discussion of this topic - if not as a background contours often indistinct - the ancient yet very modern problem of financial ties between pharmaceutical companies and clinical research, well documented recently on " The Science " (4 ), and raised on BlogScire ( 5 ) , JAMA ( 6 ) . Nor does it intend to address the thorny issue here, which is closely related to the previous trials of the hidden topic , the complexity and the implications on the clinical level is certainly not unprepared our qualified partners (7).
The BIDA, as they say, joins these protocols - even with the limitations that seem to underlie - and not replace them, unless the patient is to reject them, according to the right to freedom of Cure, widely bestowed by national and supranational (8-11) and unless, as often happens, the proposed protocols do not demonstrate in the individual patient, the desired effectiveness.
This is also in accordance with the Code of Medical Ethics (12)
It is, in brief, of a set of drugs, infused intravenously, which have the common feature of almost constantly be "natural". In the sense that these substances are normally present in the body and are synthesized or expressed by some pharmaceutical industries and their use is authorized by AIFA.
Taken together, these substances are entrusted to the organism, at therapeutic doses, which uses them to trigger the mechanisms of protection of the organs and systems involved in the complex morbid picture.
A holistic reading of the pathological phenomena definitely helps to interpret this approach. And common heritage of all medical knowledge that self-healing is one of the roads leading to the wellbeing and to the resolution of serious morbid events.
The BIDA supports and / or activates the self-healing processes, either through the known effects of the individual drugs, described below, and are unlikely to be complex and hard to investigate beneficial effects of interaction between the molecules and their metabolites and biochemical reactions, humoral, enzymatic from these unsolicited (13, 14). It is a problematic aspect that is expressed in every multidrug therapy (15).
These mechanisms of action that make the BIDA effective in many morbid conditions, without regsitrare, after many years of its application, no side effects, according to the principle "primum non nocere" foundation of the Hippocratic Oath (16) and code of Medical Ethics, which it is based (12).
In light of these considerations, it is difficult to reconcile the demand, sometimes solicited investigating the practice "therapeutic" according to the rules - however rarely practiced - the use of drugs "off label" consensus, according to the procedures of prescription and administration grant informed consent from the patient and the use of off-label practice would seem obsolete or, at least, applied in a non-pregnant. We invite you to consider in this section also established therapies to counter existential conditions common, but they tend to extend the domain of the disease in terms of quantity (17), an example for all the lowering of cholesterol levels considered normal (18) or levels of blood pressure.
The drugs used in the BIDA, all recorded by governmental authorities in the field of international marketing authorization of drugs, can be combined in different ways, and at different doses, depending on the clinical history of the patient, the profile diatesico, familiarity ... in harmony axiom known to every student in medicine, according to which "there is a sick person and not the disease," the treatment is customized.
Drugs of BIDA are as follows. For each of these shows the short pharmacokinetic profile recognized in the registration phase. They also reported some bibliographic entries that demonstrate how the insights of Dr. Emanuele Ugo D'Abramo are today important scientific confirmation.
Fructose 1,6 diphosphate
The phosphate is the major anion in the intracellular fluid. It is present in the plasma in the form of both inorganic and organic, which constituent of phospholipids, enzyme cofactors and nucleic acids. Phosphate plays a primary role in a variety of physiological processes, such as being implicated in the formation of high energy bonds (ATP), in the transport of oxygen to the tissues (2,3-diphosphoglycerate), in the regulation of glycolysis, in the maintenance of plasma and urinary pH (19, 20, 21)
The parenteral administration of the hypothalamic phospholipids is able to activate the metabolism hypothalamic increasing dopamine turnover, the activity of tyrosine hydroxylase and adenilcyclasis’, resulting in accumulation of CAMP.
This pharmacological effect is reflected in particular on the functionality of the hypothalamic-pituitary.
Recall also as phospholipids are essential components of cell membranes and their administration ensures its integrity and stability (22)
It’s an aminoacid present almost ubiquitously distributed in tissues and body fluids, where it is involved in important biological processes in humans and animals primarily as a coenzyme and as a methyl donor ( transmethylation reactions ) . Transmethylation is also essential in the development of the phospholipid bilayer of the cell membranes and contributes to the fluidity of the membranes. Ademetionine can penetrate the blood-brain barrier and the transmethylation ademetionine mediatata is critical in the formation of neurotransmitters in the central nervous system including catecholamines (dopamine, noraderenalina, epinephrine, serotonin, melatonin, and histamine) . The ademetionine is also physiological precursor of sulfur compounds (cysteine, taurine, glutathione, CoA , etc.) In the reactions of transsulfuration, Glutathione, the most powerful antioxidant in the liver is important in hepatic detoxification. Ademetionine increases the levels of hepatic glutathione in patients with liver disease caused by alcohol or not. Both the folate vitamin B12 are essential co-factors in the metabolism and restoration dell'Ademetionina .
The transfer of the methyl group (transmethylation) dall'Ademetionina in biological molecules such as hormones, neurotransmitters , nucleic acids , proteins , phospholipids is a fundamental step in the metabolic processes of the organism (23-26 )
Glutathione (GSH) is a tripeptide composed of physiological glutamic acid, cysteine and glycine, which is involved in many biological processes and plays an important role in detoxification reactions , protecting cells from the harmful action of xenobiotic agents , oxidants and environmental intracellular (free radicals , reactive oxygen intermediates) and radiation. Preclinical and clinical studies have demonstrated the protective role of glutathione in many pathological situations which cause cellular damage, such as poisoning from substances such as ethyl alcohol, paracetamol, salicylates, Phenobarbital, tricyclic antidepressants, organo-phosphate insecticides, etc. . Have also been noted that many chemotherapeutic reduce tissue levels of intracellular GSH and endogenous, aggravating the condition of oxidative stress induced by the tumor.
As regards in particular the neurotoxicity from chemotherapy such as cisplatin and derivatives, it is believed that it is due to the accumulation of platinum in the peripheral nervous system, in particular in the posterior nerve root ganglia . In the case of oxaliplatin seems that the accumulation of platinum is due to a slower elimination rather than to a greater deposit. This suggests the use of agents such as glutathione which is able to prevent the initial accumulation of platinum in the ganglia of the nerve roots rear .
Numerous clinical studies have confirmed this effect of glutathione : they show that the infusion of glutathione prior to antiblastic administration in patients with ovarian cancer , gastric cancer and colon cancers and rectum too, exerts effective protection against the nephro - and neurotoxicity caused by cisplatin and oxaliplatin , if necessary allowing the attainment of higher cumulative dosing of antineoplastic (27-30 )
Carnitine is a natural constituent of the cell in which it plays a vital role in the production and transportation of energy.
The carnitine is, in fact , the only factor not vicariabile for the penetration of long chain fatty acids into the mitochondria and their beginning to the beta-oxidation ; also controls the transport of the energy produced from the mitochondria to the cytoplasm through the modulation of the enzyme adenine - nucleotide translocase .
The highest concentration of tissue carnitine is in skeletal muscle and in the myocardium, the latter, although it is able to use various substrates for energy purposes , it normally serves fatty acids .
Therefore Carnitine plays an essential role in cardiac methabolism as the fatty acid oxidation is strictly dependent on the presence of adequate amounts of the substance.
Experimental studies have shown that under various conditions of stress, acute ischemia, myocarditis of diphtheria is a demonstrable lowering of myocardial tissue levels of carnitine (31, 32). Many animal models have confirmed a positive activity of carnitine in various artificially induced alterations of cardiac function: acute ischemia and chronic states of heart failure , heart stroke, myocarditis diphtheria , cardiotoxicity from drugs (propranolol , adriamycin) .
Ascorbic acid, due to its molecular nature (structure eno-diol) acts as a hydrogen carrier in the redox enzyme systems that are essential in the processes of the intermediate metabolism and cellular respiration.
In the course of clinical practice, its antioxidant power has been used in clinical settings varied (33-38)
N5-methyltetrahydrofolate calcium pentahydrate
For its physiological characteristics of the molecule 5-MTHF is used by the body as such, ie without undergoing further biotransformation processes. It is the physiological form of transport of folic acid in plasma, where it accounts for almost all of the circulating folate. It is readily absorbed from the digestive tract and, therefore, is distributed to all tissues including the CNS, it is in fact picked up by the choroid plexus in the cerebrospinal fluid, where its concentration is equal to three times that of the blood (39-41).
The BIDA then place their belongings on the side of anti-oxidation, stabilization of cell membranes, the release of free radicals. The restore energy levels, immunological and biochemical basis of the typical self-defense mechanisms, generates media useful for healing various disease conditions.
The BIDA has shown, with or without the treatment protocol according to the wishes of the patients, the beneficial effects in the treatment of various diseases, already describe in the box “The treatment” of this web site.
1. Parrillo S, Perper A, Christensen D, Glassman ES. A Holistic Approach to Disaster Medical Education. Prehosp Disaster Med. 2013 Feb 1:1-2.
2. Ansmann EB, Hecht A, Henn DK, Leptien S, Stelzer HG. The future of monitoring in clinical research – a holistic approach: Linking risk-based monitoring with quality management principles.Ger Med Sci. 2013;11:Doc04. doi: 10.3205/000172. Epub 2013 Feb 4.
3. Francesco Bottaccioli, Psico Neuro Endocrino Immunologia, RED, 2011 (in Italian)
4. Charles Seife, La ricerca medica è affidabile?, La Scienze, feb. 2013, 31-39
5. Danilo Diodoro, Post 121: Chi si fida di Big Pharma?, http://www.scire-ausl.bo.it/ (in italian)
6. Howard Bauchner, Restoring Confidence in Pharmaceutical Industry, JAMA, 2013, 309 (6), 607-609
7. http://www.alltrials.net/ BMJ, since 2012, GIMBE, since 2012, et al.
8. Norimberga Code, 1946
9. W.M.A. (World Medical Association) Dichiarazione di Helsinki, 1964
10. Costituzione Italiana, Articolo 32, 1947
11. Cassazione, Principio della libertà terapeutica del Medico, sentenza n. 301/2001, sezione IV, depositata il 25 gennaio 2005 (in italian)
12. Codice di Deontologia Medica, Articoli 4, 13, 15, 16 dicembre 2006 (in italian)
13. Purchit V, Rapaka R, Kwon OS, Song BJ, Roles of alcohol and tobacco exposure in the development of hepatocellular carcinoma. Life Sci. 2013 Jan 17;92(1):3-9
14. Papakostas V., Cassiello CF., Iovieno N., Folates and S-adenosylmethionine for major depressive disorder. Can. J. Psychiatry. 2012, Jul; 57(7), 406-413
15. Autori Vari, Fondamenti di assistenza geriatrica: farmacologia clinica, in Manuale Merck di Terapia. 2013 (in italian)
16. Hippocrates Oath
17. Domenighetti G, Satolli R., EBM e cittadini (troppa medicina?) in A. LiberatiEtica, conoscenza e Sanità, Il Pensiero Scientifico Editore, Roma, 2005, p. 164 (in Italian)
18. Moynihan R., Cassel A., Selling sickness, Nation Book, San Francisco, 2005
19. Mor F., Izak M., Cohen IR., Identification of aldolase as a target antigen in Alzheimer's disease, J. Immunol. 2005 Sep. 1, 175(5), 3439-45
20. Riedel BJ., Gal J., Ellis G., Marangos PJ., Fox AW., Royston D., Myocardial protection using fructose-1,6-diphosphate during coronary artery bypass graft surgery: a randomized, placebo-controlled clinical trial. Anesth. Analg. 2004, Jan. 98(1), 20-29
21. Villani C., Fructose 1,6 diphosphate and its use in therapy, Gazz. Med. Ital., 1963, Nov. 122, 359-364
22. Tayebati SK, Amenta F., Choline contains phospholipids, relevance to brain functional pathway. In Clinical Chemistry and Laboratory Medicine, 2013, 51, pp. 1-9
23. Mato JM, Martinez Chantar ML, Lu SC, S-adenosylmethionine metabolism and liver disease. Ann. Hepatol. 2013 Mar;12(2):183-9.
24. Sukhanov DS, Zabolotnykh NV, Vasileva SN, Vitovskaia ML, The effect of runihol and exogenous S-adenosyl-L-methionine on the morphological pattern of the liver upon hepatotoxic exposure to reserve-series antituberculous drugs . Arkh. Patol..2012 Sep-Oct;74(5):51-4, 56
25. Lu SC, Mato JM, S-adenosylmethionine in liver health, injury, and cancer.Physiol. Rev. 2012 Oct;92(4):1515-1542.
26. Pan WH, Chang YP, Yeh WT, Guei YS, Lin BF, Wei IL, Yang FL, Liaw YP, Chen KJ, Chen WJ, Co-occurrence of anemia, marginal vitamin B6, and folate status and depressive symptoms in older adults. J. Geriatri. Psychiatry Neurol. 2012 Sep;25(3):170-8
27. Bao OY, Geng DD, Xue JW, Zhou G, Gu SY, Zhang C, Glutathione-mediated drug release from Tiopronin-conjugated gold nanoparticles for acute liver injury therapy.Int. J. Pharm. 2013 Feb 14. pii: S0378-5173(13)00150-6
28. Liddell JR, Obando D, Liu J, Ganio G, Volitakis I, San Mok S, Crouch PJ, White AR, Codd R,Lipophilic adamantyl- or deferasirox-based conjugates of desferrioxamine B have enhanced neuroprotective capacity: Implications for Parkinson's disease. Free Radic Biol Med 2013 Feb 4. pii: S0891-5849(13)00037-3
29. Wozniak A, Masiak R, Szpinda M, Mila-Kierzenkowska C, Wozniak B, Makarewicz R, Szpinda A. Oxidative Stress Markers in Prostate Cancer Patients after HDR Brachytherapy Combined with External Beam Radiation. Oxid Med Cell Longev2012;2012:789870.
30. An L, Dani KA, Shen J, Warach S, Natural History of stroke investigation.Pilot results of in vivo brain glutathione measurements in stroke patients. J Cereb Blood Flow Metab 2012 Dec;32(12):2118-21
31. Dionne S., Elimrani I., Roy MJ, Qureshi IA, Sarma DR, Levy E, Seidman EG,Studies on the chemopreventive effect of carnitine on tumorigenesis in vivo, using two experimental murine models of colon cancer. Nutr. Cancer. 2012; 64(8): 1279-87
32. Bin Aleem S, Hussain MM, Farooq Y, Levo-carnitine reduces oxidative stress and improves contractile functions of fast muscles in type 2 diabetic rats. Iran Biomed J.2012, 17(1): 29-35
33. Riccioni G, D’Orazio N, Salvatore C, Franceschelli S, Pesce M, Speranza L,Carotenoids and vitamins C and E in the prevention f cardiovascular disease. Int. J. Vitam. Nutr. Res. 2012, Feb, 82(1): 15-26
34. Kodama M, Kodama T, Vitamin C and genesis of autoimmune disease and allergy (review). In Vivo, 1995, May-Jun 9(3): 231-238
35. Romero Alvira D, Guerrero Navarro L, Gotor Làzaro MA, Roche Collado E,Oxidative stress and infectious disease. An Med Interna, 1995, Mar, 12(3) 139-149
36. Cortés-Joffré M, Rueda JR, Corsini Munoz G, Fonseca-Cortés C, Caraballoso M, Bonfill Cosp X Drugs for preventing lung cancer in healthy people. Cochrane Database Syst Rev, 2012, Oct, 17, 10. CD002141
37. Verrax J, Beck R, Dejeans N, Glorieux C, Sid B, Pedrosa RC, Benites J, Vàsquez D, Valderrama JA, Calderon PB, Redox-active quinines and ascrobate: an innovative cancer therapy that exploits the vulnerability of cancer cells to oxidative stress.Anticancer Agents Med Chem, 2011, Feb, 11(2), 213-221